New Products - VPRIV

VPRIV **(velaglucerase alfa (ghu))** is a glycoprotein with the same amino acid sequence as the naturally occurring human enzyme, glucocerebrosidase. Velaglucerase alfa (ghu) supplements or replaces beta-glucocerebrosidase, the enzyme that catalyses the hydrolysis of glucocerebroside to glucose and ceramide in lysosomes, reducing the amount of accumulated glucocerebroside and correcting the pathophysiology of Gaucher disease. VPRIV increases haemoglobin concentration and platelet counts and reduces spleen volumes in patients with type 1 Gaucher disease. It also reduces liver volumes. VPRIV is indicated for long-term enzyme replacement therapy (ERT) for paediatric and adult patients with type 1 Gaucher disease associated with at least one of the following clinical manifestations: anaemia, thrombocytopaenia, hepato-splenomegaly. VPRIV is available as a powder for solution for intravenous infusion in single use glass vials containing 400 units (10 mg) in packs of 1's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.